XELIRI plus bevacizumab compared with FOLFIRI plus bevacizumab as first-line setting in patients with metastatic colorectal cancer: experiences at two-institutions.


UYGUN K., BILICI A., KAYA S., Oven U., YILDIZ R., TEMIZ S., et al.

Asian Pacific journal of cancer prevention : APJCP, cilt.14, ss.2283-8, 2013 (SCI Expanded İndekslerine Giren Dergi)

  • Cilt numarası: 14
  • Basım Tarihi: 2013
  • Doi Numarası: 10.7314/apjcp.2013.14.4.2283
  • Dergi Adı: Asian Pacific journal of cancer prevention : APJCP
  • Sayfa Sayısı: ss.2283-8